Tutte le categorie
| Product Name | Descrizione | Action |
|---|---|---|
| Amivantamab,Rybrevant,EGFR, cMet (MET),JNJ-61186372,anticorpo bispecifico EGFR/c-MET,completamente bispecifico IgG1 umano,immunoterapia oncologica / NSCLC biologica, CAS n.2171511-58-1 | Trade Name : Rybrevant Target : EGFR, cMet (MET) Molecular Type : Bispecific Antibody Sales in 2025 (Millions of USD) : 179(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Polatuzumab vedotin,Polivy,CD79B,RG7596,ADC,terapia mirata CD79b,inibitore dei microtubuli,ADC oncologico / DLBCL ADC / linfoma ADC,infusione endovenosa, CAS n. 1313206-42-6 | Trade Name : Polivy Target : CD79B Molecular Type : ADC Sales in 2025 (Millions of USD) : 850(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Obinutuzumab, Gazyva, CD20, GA101, CAS n. 949142-50-1, anticorpo monoclonale anti-CD20 (tipo II), anticorpo IgG1 umanizzato,Oncologia biologica / CLL biologica / Linfoma follicolare biologica | Trade Name : Gazyva Target : CD20 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 784(First three quarters) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Ivonescimab ,YIDAFANG®(Nomi commerciali approvati per l'uso in Cina) ,AK112 ,Anticorpo bispecifico PD-1/VEGF ,Immunoterapia oncologica / Terapia anti-angiogenica ,Anticorpo bispecifico PD-1/VEGF ,N. CAS 2428381-53-5 | Trade Name : YIDAFANG® (Trade names approved for use in China) Target : N/A Molecular Type : PD-1/VEGF Bispecific antibody Sales in 2025 (Millions of USD) : 28(In 2024) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this ... |
|
| Datopotamab deruxtecan-dlnk | Trade Name : Datroway Target : TROP-2 Molecular Type : ADC Sales in 2025 (Millions of USD) : 10(First Quarter) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tenecteplase | Trade Name : Metalyse Target : Fibrin Molecular Type : Recombinant Protein Sales in 2025 (Millions of USD) : 1780(estimate) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with us. |
|
| Tarlatamab, Imdelltra, DLL3 e CD3, AMG 757, Immunoterapia oncologica / SCLC biologica, Infusione endovenosa, Citotossicità mediata dalle cellule T, Engager bispecifico delle cellule T, CAS n. 2307488-83-9 | Trade Name : Imdelltra Target : DLL3&CD3 Molecular Type : Bispecific T-cell Engager Sales in 2025 (Millions of USD) : 215(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in ... |
|
| Serplulimab ,HANSIZHUANG ,PD-1 ,Hetronifly ,HLX10 ,Inibitore del checkpoint immunitario anti-PD-1 ,Anticorpo monoclonale IgG4 umanizzato ,Anticorpo monoclonale ,N. CAS 2231029-82-4 | Trade Name : HANSIZHUANG Target : PD-1 Molecular Type : Monoclonal Antibody Sales in 2025 (Millions of USD) : 82(First half of the year) All detailed product information shall be subject to the issued final COA. Should you need further in-depth documentation for this item, kindly get in touch with ... |
